ConductScience.org, home

Paper42158317

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease.

Shao W and 3 others. Research (Wash D C), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease. Papers, record 42158317. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42158317

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease.
PubMed
Journal
Research (Wash D C)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shao WWenxiahttps://orcid.org/0000-0002-2041-5743
2Liu JJiayu
3Sun MMing
4Yu DDaojun

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136109639Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.Nat Med2022https://conductscience.org/library/papers/36109639PubMed
234347960CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.N Engl J Med2021https://conductscience.org/library/papers/34347960PubMed
335500125Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.Blood2022https://conductscience.org/library/papers/35500125PubMed
438777376BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.Ann Rheum Dis2024https://conductscience.org/library/papers/38777376PubMed
539453747Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs.Proc Natl Acad Sci U S A2024https://conductscience.org/library/papers/39453747PubMed
623041722Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.Leukemia2013https://conductscience.org/library/papers/23041722PubMed
740955314HLA-A2 CAR/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40955314PubMed
829385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
939013470Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.Cell2024https://conductscience.org/library/papers/39013470PubMed
1040355709The race to reset autoimmune diseases.Nat Rev Drug Discov2025https://conductscience.org/library/papers/40355709PubMed
1141316450Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.J Hematol Oncol2025https://conductscience.org/library/papers/41316450PubMed
1238175598Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy.Clin Chem2024https://conductscience.org/library/papers/38175598PubMed
1339428507MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis.J Neuroinflammation2024https://conductscience.org/library/papers/39428507PubMed
1441534043CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.N Engl J Med2026https://conductscience.org/library/papers/41534043PubMed
1538697115Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.Neuron2024https://conductscience.org/library/papers/38697115PubMed
1639833408Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.Nat Med2025https://conductscience.org/library/papers/39833408PubMed
1739874224CD19-CAR T-cell therapy induces deep tissue depletion of B cells.Ann Rheum Dis2025https://conductscience.org/library/papers/39874224PubMed
1837561596Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice.J Clin Invest2023https://conductscience.org/library/papers/37561596PubMed
1933053469Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.Cell Immunol2020https://conductscience.org/library/papers/33053469PubMed
2041080554The half-century odyssey of regulatory B cells: from Breg discovery to emerging frontiers.Front Immunol2025https://conductscience.org/library/papers/41080554PubMed

See all 81 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42158317

GET https://conductscience.org/api/papers/v1/42158317/references?page=2